Market Closed -
Hong Kong S.E.
03:40:05 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
0.95
HKD
|
+6.74%
|
|
+7.95%
|
-30.66%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,728
|
3,432
|
2,950
|
768.6
|
957.6
|
927.7
|
Enterprise Value (EV)
1 |
1,359
|
3,311
|
2,836
|
927.6
|
1,058
|
1,242
|
P/E ratio
|
14.7
x
|
64.2
x
|
42.9
x
|
50.5
x
|
-25.3
x
|
-24.9
x
|
Yield
|
0.59%
|
0.16%
|
0.24%
|
0.9%
|
-
|
-
|
Capitalization / Revenue
|
3.74
x
|
8.42
x
|
6.06
x
|
1.99
x
|
1.95
x
|
1.64
x
|
EV / Revenue
|
2.94
x
|
8.13
x
|
5.83
x
|
2.41
x
|
2.15
x
|
2.2
x
|
EV / EBITDA
|
9.66
x
|
51.4
x
|
29
x
|
11.1
x
|
14.6
x
|
25.1
x
|
EV / FCF
|
-17
x
|
-30.5
x
|
23.6
x
|
-5.38
x
|
7.01
x
|
-7.81
x
|
FCF Yield
|
-5.89%
|
-3.28%
|
4.24%
|
-18.6%
|
14.3%
|
-12.8%
|
Price to Book
|
2.81
x
|
5.1
x
|
4.47
x
|
1.17
x
|
1.56
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
800,000
|
800,000
|
770,434
|
760,744
|
758,210
|
745,034
|
Reference price
2 |
2.160
|
4.290
|
3.830
|
1.010
|
1.263
|
1.245
|
Announcement Date
|
19-04-29
|
20-05-14
|
21-04-23
|
22-04-28
|
23-04-28
|
24-04-26
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
462.1
|
407.4
|
486.9
|
385.7
|
491.8
|
565.6
|
EBITDA
1 |
140.7
|
64.38
|
97.96
|
83.35
|
72.33
|
49.56
|
EBIT
1 |
124.6
|
48.24
|
81.55
|
65.92
|
45.41
|
21.45
|
Operating Margin
|
26.96%
|
11.84%
|
16.75%
|
17.09%
|
9.23%
|
3.79%
|
Earnings before Tax (EBT)
1 |
123.8
|
63.81
|
78.4
|
23.79
|
-30.99
|
-29.45
|
Net income
1 |
101.9
|
53.43
|
70.13
|
16.64
|
-34.6
|
-36.28
|
Net margin
|
22.05%
|
13.12%
|
14.4%
|
4.32%
|
-7.04%
|
-6.41%
|
EPS
2 |
0.1466
|
0.0668
|
0.0892
|
0.0200
|
-0.0500
|
-0.0500
|
Free Cash Flow
1 |
-79.97
|
-108.6
|
120.3
|
-172.6
|
150.9
|
-159
|
FCF margin
|
-17.31%
|
-26.67%
|
24.72%
|
-44.75%
|
30.68%
|
-28.11%
|
FCF Conversion (EBITDA)
|
-
|
-
|
122.84%
|
-
|
208.6%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
171.58%
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0128
|
0.006700
|
0.009100
|
0.009100
|
-
|
-
|
Announcement Date
|
19-04-29
|
20-05-14
|
21-04-23
|
22-04-28
|
23-04-28
|
24-04-26
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
159
|
100
|
314
|
Net Cash position
1 |
370
|
121
|
114
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
1.908
x
|
1.387
x
|
6.334
x
|
Free Cash Flow
1 |
-80
|
-109
|
120
|
-173
|
151
|
-159
|
ROE (net income / shareholders' equity)
|
25.5%
|
8.05%
|
9.35%
|
2.53%
|
-5.46%
|
-6.18%
|
ROA (Net income/ Total Assets)
|
7.37%
|
2.58%
|
4.22%
|
3.32%
|
2.19%
|
1%
|
Assets
1 |
1,383
|
2,073
|
1,663
|
501.1
|
-1,579
|
-3,645
|
Book Value Per Share
2 |
0.7700
|
0.8400
|
0.8600
|
0.8600
|
0.8100
|
0.7600
|
Cash Flow per Share
2 |
0.7000
|
0.4100
|
0.3900
|
0.1100
|
0.1700
|
0.0500
|
Capex
1 |
104
|
57.8
|
58.6
|
110
|
23.9
|
66.2
|
Capex / Sales
|
22.58%
|
14.19%
|
12.05%
|
28.56%
|
4.85%
|
11.71%
|
Announcement Date
|
19-04-29
|
20-05-14
|
21-04-23
|
22-04-28
|
23-04-28
|
24-04-26
|
|
1st Jan change
|
Capi.
|
---|
| -30.66% | 84.21M | | +20.28% | 43.27B | | +25.28% | 22.92B | | +19.25% | 15.43B | | +13.43% | 12.95B | | +43.76% | 11.83B | | -7.79% | 6.91B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.55B |
Generic Pharmaceuticals
|